• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Jazz Pharmaceuticals plc

    7/14/25 4:07:59 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JAZZ alert in real time by email
    DEFA14A 1 d927302ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material Pursuant to Section 240.14a-12

    JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     
     


    The following e-mail was sent to employees of Jazz Pharmaceuticals plc on July 14, 2025.

    Subject: From Neena Patil: An important reminder - Please vote your shares

     

    LOGO

    Dear Jazzicians,

    I am writing in connection with our 2025 Annual General Meeting of Shareholders (AGM) approaching on 24 July because many of you are shareholders in addition to being employees of Jazz Pharmaceuticals.

    Please take a moment now to ensure that your shares are represented at this important meeting. As a Jazz Pharmaceuticals shareholder, your vote is very important.

    We have a number of important proposals being voted on at the AGM. Jazz Pharmaceuticals’ board of directors and management team recommend that you vote your shares “FOR” each of the director nominees and “FOR” the other three proposals. Please refer to our proxy statement and the additional proxy materials that have been filed with the SEC for more details regarding the nominees and proposals.

    If you were a shareholder on the record date 29 May 2025, you should have received instructions in the mail or electronically from your bank or broker about how to vote your shares and more information is provided below about E*Trade notifications.

    Only shareholders of record at the close of business on the record date may vote at the AGM.

    We encourage you to vote your shares as soon as possible.


    For E*Trade employee stock plan services, please call +1.800.838.0908 (or 1.650.599.0125 if outside the US).

    You may also reach out to Aislinn Doody or Julie Panigrahi for further assistance.

    Thank you for your continued contributions to the growth and success of Jazz Pharmaceuticals and thank you in advance for voting promptly.

    E*Trade Notifications:

    If you hold shares through E*Trade and receive communications electronically, you should have received an email on or close to June 14th, from E*Trade with a “from” address of [email protected] with the subject heading “Vote now! JAZZ PHARMACEUTICALS PLC Annual Meeting” with instructions about how to vote your shares (please check your “spam” or ‘junk” folder if you did not receive it). If you do not receive communications from E*Trade electronically, you should have received instructions about how to vote your shares in the mail.

     

    LOGO

    Get the next $JAZZ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JAZZ

    DatePrice TargetRatingAnalyst
    7/15/2025$152.00Buy
    Deutsche Bank
    3/7/2025$145.00 → $179.00Neutral → Buy
    UBS
    2/26/2025Overweight → Neutral
    Cantor Fitzgerald
    2/13/2025$130.00 → $170.00Equal Weight → Overweight
    Wells Fargo
    12/12/2024$140.00 → $175.00Equal-Weight → Overweight
    Morgan Stanley
    6/5/2024$169.00Buy
    Goldman
    1/3/2024$160.00Outperform
    Robert W. Baird
    11/27/2023$170.00 → $135.00Buy → Neutral
    UBS
    More analyst ratings

    $JAZZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director O'Keefe Kenneth W was granted 3,507 units of Ordinary Shares and covered exercise/tax liability with 1,805 units of Ordinary Shares, increasing direct ownership by 6% to 28,672 units (SEC Form 4)

    4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

    8/11/25 5:55:53 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Cook Jennifer E. was granted 3,507 units of Ordinary Shares and covered exercise/tax liability with 1,805 units of Ordinary Shares, increasing direct ownership by 19% to 10,837 units (SEC Form 4)

    4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

    8/11/25 5:47:29 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Enright Patrick G was granted 3,507 units of Ordinary Shares and covered exercise/tax liability with 1,805 units of Ordinary Shares, increasing direct ownership by 7% to 26,379 units (SEC Form 4)

    4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

    8/11/25 5:46:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAZZ
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 12, 2021 - FDA Grants First of its Kind Indication for Chronic Sleep Disorder Treatment

    For Immediate Release: August 12, 2021 The U.S. Food and Drug Administration today approved a new indication for Xywav for idiopathic hypersomnia (IH) in adults. IH is an uncommon chronic sleep disorder that causes people to be excessively sleepy during the day even after a good night's sleep. Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution is already approved for the treatment of catapl

    8/12/21 4:25:43 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAZZ
    SEC Filings

    View All

    SEC Form 144 filed by Jazz Pharmaceuticals plc

    144 - Jazz Pharmaceuticals plc (0001232524) (Subject)

    8/8/25 2:40:17 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Jazz Pharmaceuticals plc

    10-Q - Jazz Pharmaceuticals plc (0001232524) (Filer)

    8/6/25 7:33:51 AM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jazz Pharmaceuticals plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Jazz Pharmaceuticals plc (0001232524) (Filer)

    8/5/25 4:08:42 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAZZ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Deutsche Bank initiated coverage on Jazz Pharma with a new price target

    Deutsche Bank initiated coverage of Jazz Pharma with a rating of Buy and set a new price target of $152.00

    7/15/25 8:41:59 AM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jazz Pharma upgraded by UBS with a new price target

    UBS upgraded Jazz Pharma from Neutral to Buy and set a new price target of $179.00 from $145.00 previously

    3/7/25 8:10:15 AM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jazz Pharma downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Jazz Pharma from Overweight to Neutral

    2/26/25 1:51:25 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAZZ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mulligan Seamus bought $9,993,082 worth of Ordinary Shares (101,621 units at $98.34) (SEC Form 4)

    4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

    5/13/25 6:51:34 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson Philip L was granted 15,932 units of Ordinary Shares and bought $1,435,800 worth of Ordinary Shares (12,000 units at $119.65) (SEC Form 4)

    4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

    3/5/24 7:28:40 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAZZ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025

    DUBLIN, Aug. 20, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) will host an investor webcast on Wednesday, August 27, 2025, at 4:30 p.m. EDT / 9:30 p.m. IST to provide an overview of clinical data, patient need and commercialization strategy for Modeyso™ (dordaviprone). Modeyso was approved under accelerated approval by the U.S. Food and Drug Administration (FDA) on August 6, 2025, for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy.1 Modeyso is the first and only treatment option approved by the FDA for this ultra-rare and aggressive brain tumor. Jaz

    8/20/25 4:15:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355

    Saniona to receive US $42.5 million upfront; potential for development, regulatory and sales milestone payments in addition to royalties on future net sales Jazz obtains exclusive worldwide rights to develop and commercialize preclinical asset SAN2355 in epilepsy and other potential indications For U.S. media and investors only DUBLIN and COPENHAGEN, Denmark, Aug. 20, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and Saniona (Nasdaq OMX: SANION) today announce that the companies have entered into a global license agreement for Jazz to obtain exclusive worldwide rights to develop SAN2355, a highly differentiated, subtype-selective Kv7.2/Kv7.3 activator in preclinical development

    8/20/25 7:30:00 AM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma

    Modeyso is the first treatment option for this ultra-rare and aggressive brain tumor, which primarily affects children and young adults Accelerated approval based on an overall response rate in patients with progressive disease following prior therapy Company to host investor webcast on August 27, 2025 For U.S. media and investors only DUBLIN, Aug. 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Modeyso™ (dordaviprone) for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease fo

    8/6/25 3:07:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAZZ
    Financials

    Live finance-specific insights

    View All

    Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025

    DUBLIN, Aug. 20, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) will host an investor webcast on Wednesday, August 27, 2025, at 4:30 p.m. EDT / 9:30 p.m. IST to provide an overview of clinical data, patient need and commercialization strategy for Modeyso™ (dordaviprone). Modeyso was approved under accelerated approval by the U.S. Food and Drug Administration (FDA) on August 6, 2025, for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy.1 Modeyso is the first and only treatment option approved by the FDA for this ultra-rare and aggressive brain tumor. Jaz

    8/20/25 4:15:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025

    DUBLIN, July 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that it will report its 2025 second quarter financial results on Tuesday, August 5, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. EDT / 9:30 p.m. IST to discuss 2025 second quarter financial results and provide a business and financial update. Interested parties may register for the call in advance here or via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. A repla

    7/22/25 4:15:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025

    DUBLIN, April 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that it will report its 2025 first quarter financial results on Tuesday, May 6, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2025 first quarter financial results and provide a business and financial update.   Audio webcast/conference call:U.S. Dial-In Number: +1 800 715 9871Ireland Dial-In Number: +353 1800 943 926Additional global dial-in numbers are available here.Passcode: 5080203 Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at

    4/22/25 4:15:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAZZ
    Leadership Updates

    Live Leadership Updates

    View All

    Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer

    – Selection Follows Robust Succession Process Led by the Board – – Bruce Cozadd to Retire as CEO and Remain Chairperson of the Board of Directors – DUBLIN, July 10, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Jazz Board of Directors has unanimously selected Renee Gala, Jazz's President and Chief Operating Officer, as the President and Chief Executive Officer, effective August 11, 2025, when she will also join the Board. She will succeed co-founder, Chairperson and CEO Bruce Cozadd, who informed the Board in December 2024 of his intent to retire as CEO upon the identification of the Company's next leader. This appointment reflects a key milestone in t

    7/10/25 7:30:00 AM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jazz Pharmaceuticals Announces CEO Succession Plan

    Bruce Cozadd, Co-Founder, Chairperson and CEO, Plans to Retire as CEO Upon Appointment of Successor by the End of 2025; Will Continue as Chair of the Board Mr. Cozadd Has Led Growth of Company from Founding to $4 Billion+ in 2024 Expected Total Revenue Board Will Lead Comprehensive Internal and External Search for New CEO; Intended to be Completed in 2025 DUBLIN, Dec. 16, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that Bruce Cozadd, Co-Founder, Chairperson and Chief Executive Officer (CEO), has informed the Board of Directors of his intent to retire from his role as CEO upon appointment of the Company's next leader, expected by the end of 2025. The Board wil

    12/16/24 4:05:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting

    Ms. Hamill brings extensive experience and proven leadership focused on commercial growth and shareholder value DUBLIN, July 25, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced the election of a new independent director, Laura Hamill, to its Board of Directors. Ms. Hamill, a 35-year veteran of the pharmaceutical industry brings broad executive leadership and global commercial operations expertise to the company's Board. Ms. Hamill's election follows the appointment of Patrick Kennedy earlier this year and reflects Jazz's continued focus on Board renewal. At the Annual General meeting held today, shareholders not only elected Ms. Hamill and Mr. Kennedy but also re-

    7/25/24 4:05:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAZZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Jazz Pharmaceuticals plc (Amendment)

    SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)

    2/13/24 5:07:58 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Jazz Pharmaceuticals plc (Amendment)

    SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)

    9/11/23 1:33:44 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Jazz Pharmaceuticals plc (Amendment)

    SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)

    2/9/23 11:25:15 AM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care